Thirty patients without any prior chemotherapy and histologically proved non-oat-cell advanced lung cancer entered a randomized trial comparing a combination chemotherapeutic regimen (cyclophosphamide, methotrexate, BCNU) and the same combination plus intradermic BCG. Twenty-nine patients were evaluable for survival. Mean survival was 11 and 3.5 months for chemotherapy and chemoimmunotherapy group, respectively. The difference was statistically significant (P < 0.025). A tumor enhancement can be postulated. Skin tests before treatment (PPD, Candida, Varidase) seem to be prognostic for survival.
Get full access to this article
View all access options for this article.
References
1.
AmjelJ.L., BerardetM.: Factor time for active immunotherapy after cytoreductive chemotherapy.Eur. J. Cancer, 10: 89–91, 1974.
2.
BerettaG., ManaraM., NegriR., BergamiL., ConsonniT.: Valutazione comparativa di differenti tecniche di amministrazione del BCG.Atti Riunioni Integrate Oncologia, Bari, 1980.
3.
BernheimJ.L.: Immunotherapy of a solid tumour (melanoma) with BCG: A comment on the risks of enhancement.Recent Results Cancer Res., 47: 473–475, 1974.
4.
BornsteinR.S., MastrangeloM.J., SulitH., CheeD., YarbroJ.W.: Immunotherapy of melanoma with intralesional BCG.Natl. Cancer Inst. Monogr., 39: 213–220, 1973.
5.
BrownC., BrownI., Sljivi'cV.S.: Active suppression masks an underlying enhancement of antibody production in vitro by spleen cells from BCG-infected mice.Immunology, 40: 303–309, 1980.
6.
DimitrovN.V., ConrayT., SuhrlandL.G., SinghT., TeitlebaumH.: Combination therapy with Corynebacterium parvum and doxorubin hydrochloride in patients with lung cancer. (TerryW.D., WindhorstD., Eds.: Immunotherapy of Cancer: Present Status of Trial in Man).Raven Press, New York, 1978, pp. 181–190.
7.
GuttermanJ.U.: Chemoimmunotherapy of human cancer: The need for a unified drug development program.Cancer Immunol.-Immunother., 3: 153–156, 1978.
8.
GuttermanJ.U., MavlightG.M., HershE.M.: Chemoimmunotherapy of human solid tumors.Med. Clin. North Am., 60: 441–462, 1976.
9.
IsraelL.: Immune status and immunestimulation in lung cancer. In: I Tumori Polmonari, BucalossiP. Ed., pp. 319–321. Casa Editrice Ambrosiana, Milano, 1975.
10.
Ludwig Lung Cancer Study Group: Search for the possible role of « immunotherapy » in operable bronchial non-small cell carcinoma (stage I and II): A phase I study with Corynebacterium parvum intrapleurally. Cancer Immunol. Immunother., 4: 69–75, 1978.
11.
MahaleyM.S., GentryR.E., BignerD.D.: Immunobiology of primary intracranial tumours.Part 2: The evaluation of chemotherapy and immunotherapy protocols using the avian sarcoma virus glioma model. J. Neurosurg., 47: 35–43, 1977.
12.
MartinM.S., MartinF., JustraboE., MichelM.F., LagneauA.: Immunoprophylaxis and therapy of grafted rat colonic carcinoma.GUT, 18: 232–235, 1977.
13.
MathèG., Halle-PannenkoO., BourutC.: Immunemanipulation by BCG administered before or after cyclophosphamide for chemoimmunotherapy of L1210 leukemia.Eur. J. Cancer, 11: 661–665, 1975.
14.
McIllmurrayM.B., EmbletonM.J., ReevesW.G., LangmanM.J., DeaneM.: Controlled trial of active immunotherapy in management of stage IIB malignant melanoma.Br. Med. J., 1: 540–542, 1977.
15.
MortonD.L.: Introduzione alla immunoterapia dei tumori.Agg. Ancol. Clin., 2: 314–337, 1976.
16.
PinesA.: A five year controlled study of BCG and radiotherapy for inoperable lung cancer.Lancet, 1: 380–381, 1976.
17.
PorcileG.F., CanobbioL., MassaT., RubagottiA., AdamiG.F., MerlanoM.C., RossoR.: Monitoraggio immunologico del paziente neoplastico mediante skin-test.Chemioterapia Oncologica, Anno III, N. 3, pp. 230–237, 1979.
18.
PouillartP., PalangieT., SchwarzenbergL., BrugerieH., LheritierT., MathèG.: Effect of BCG on hematopoietic stem cells: Experimental and clinical study.Cancer Immunol. Immunother., 1: 163–169, 1976.
19.
ReedR.C., GuttermanJ.U., MavligitG.M., BurgessM.A., HershE.M.: Corynebacterium parvum: Preliminary report of a phase I clinical and immunological study in cancer patients. In: Corynebacterium parvum.HalpernB. Ed., Plenum Publishing Corp., New York, 1975, pp. 349–375.
20.
RoscoeP., PearceS., LudgateS., HorneN.W.: A controlled trial of BCG immunotherapy in bronchogenic carcinoma treated by surgical resection.Cancer Immunol. Immunother., 3: 115–118, 1977.
21.
SchwarzenbergL., SimmlerM.C., PicoJ.L.: Human toxicity of BCG applied in cancer immunotherapy.Cancer Immunol. Immunother., 1: 69–76, 1976.
22.
VoglerW.R., BartolucciA.A., OmuraG.A., MillerD., SmalleyR., KnopseW.H., GoldsmithA.S., ChanY.K., MurphyS.: A randomized clinical trial of remission induction consolidation and chemoimmunotherapy maintenance in adult acute leukemia.Cancer Immunol. Immunother., 3: 163–170, 1978.
